Helixmith information

This article has multiple issues. Please help improve it or discuss these issues on the talk page. (Learn how and when to remove these template messages) This article does not cite any sources. Please help improve this article by adding citations to reliable sources. Unsourced material may be challenged and removed. Find sources: "Helixmith" – news · newspapers · books · scholar · JSTOR (April 2021) (Learn how and when to remove this message) This article contains content that is written like an advertisement. Please help improve it by removing promotional content and inappropriate external links, and by adding encyclopedic content written from a neutral point of view. (May 2022) (Learn how and when to remove this message) (Learn how and when to remove this message)

Helixmith

Formerly	Byromedica Pacific Co. LTD. (1996–1999) ViroMed (1999–2019)
Company type	Public
Industry	Biotechnology
Founded	November 1996; 27 years ago (1996-11)
Founder	Sunyoung KIM, D. Phil
Headquarters	21, Magokjungang 8-ro 7-gil, Gangseo-gu, Magok, Seoul , South Korea
Key people	Sunyoung Kim (CEO), Seungshin Yu (CTO), Sinyoung Kim (COO)
Number of employees	121, 129 (2019, 2022)
Website	helixmith.com

Helixmith Co. LTD. is a biotechnology company located in Seoul, South Korea with US presence in San Diego. The company has an extensive gene therapy pipeline, including a non-viral plasmid DNA program for neuromuscular and ischemic disease, a CAR-T program targeting several different types of solid tumors, and an AAV vector program targeting neuromuscular diseases. Helixmith’s lead gene is Engensis (VM202), currently in phase III diabetic peripheral neuropathy (DPN) in the US. Engensis (VM202) is a plasmid DNA designed to simultaneously express two isoforms of hepatocyte growth factor (HGF), HGF 728 and HGF 723. In addition to DPN, Engensis is also being studied in diabetic foot ulcers (DFU), amyotrophic lateral sclerosis (ALS), coronary artery disease (CAD), claudication, and Charcot-Marie-Tooth disease (CMT).